Compare Alcon AG (ALC) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Alcon AG trades at $73.99 (market cap $36.44B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $11.3. The key difference: Alcon AG pays a 0.48% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none, and Alcon AG is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| ALC | MSTZ | |
|---|---|---|
Market Cap | $36.44B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $90.12 | $27.92 |
52-Week Low | $62.02 | $3.88 |
Enterprise Value | $40.28B | — |
Dividend Yield | 0.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.59, down slightly by 0.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $86.67 implying 17.8% upside. Recent Q2 2026 earnings beat estimates with EPS of $0.84 versus $0.77 expected, and the company raised its 2026 profitability outlook, driving positive investor sentiment. Revenue growth has been steady, reaching $10.40 billion in 2025, though net income margin dipped to 5.92%.
The outlook is positive given strong earnings beats, raised guidance, and bullish analyst ratings, but risks include elevated P/E of 57.52, high RSI levels suggesting overbought conditions, and margin pressures from rising costs. Institutional ownership trends and recent collaborations, like with RxSight, support growth, yet macroeconomic and competitive factors warrant caution.
MSTZ stock trades at $11.40, showing a 5.36% daily gain amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, while oscillators remain neutral. Financial ratios including P/E, P/S, and P/B are unavailable in current data. Recent ETF performance news indirectly references momentum names but lacks direct MSTZ coverage.
The outlook remains cautious with technical indicators favoring bearish momentum. Investment opportunity hinges on fundamental improvements currently obscured by missing financial data. Key risks include continued technical weakness and lack of clear fundamental catalysts. Investors should await earnings clarity for directional conviction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
